CSBR vs TPVG

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus 13. 5% for Champions Oncology, Inc. (CSBR). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate TriplePoint Venture Growth BDC Corp. (TPVG) a "Hold" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 9x versus Champions Oncology, Inc. at 18. 2x.

Over the past 5 years, TriplePoint Venture Growth BDC Corp.

(TPVG) delivered a total return of -13. 5%, compared to -40. 9% for Champions Oncology, Inc. (CSBR). Over 10 years, the gap is even starker: TPVG returned +93. 3% versus CSBR's +47. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Champions Oncology, Inc.

(CSBR) is the lower-risk stock at 0. 38β versus TriplePoint Venture Growth BDC Corp. 's 0. 83β — meaning TPVG is approximately 117% more volatile than CSBR relative to the S&P 500. On balance sheet safety, TriplePoint Venture Growth BDC Corp. (TPVG) carries a lower debt/equity ratio of 133% versus 162% for Champions Oncology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus 13. 5% for Champions Oncology, Inc. (CSBR). On earnings-per-share growth, the picture is similar: Champions Oncology, Inc. grew EPS 161. 1% year-over-year, compared to 48. 8% for TriplePoint Venture Growth BDC Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus 8. 3% for Champions Oncology, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus 8. 5% for CSBR. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, TPVG (17.

1% yield) pays a dividend. CSBR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), 17. 1% yield). Both have compounded well over 10 years (TPVG: +93. 3%, CSBR: +47. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CSBR (Healthcare) and TPVG (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CSBR is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock. TPVG pays a dividend while CSBR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.